"Among other findings, the Company will highlight that Apabetalone treatment illustrated statistically significant improvements compared to top standard of care placebo in cardiovascular disease patients with moderate to severe cognitive decline."

Ambiguity - are they referring to improvement in cardiovascular disease patients that happen to have cognitive decline (sub-group) or improvements in cognitive decline patients that happen to be cardiovascular disease patients also? Can be read two ways. This ambiguity might just allow them to make the statement we hope that they are and not cross the embargo line. I reiterate, if it is okay to openly report on cognition efficacy, why not tell us long before this.